Advertisment
Which groups benefited most from an ECHELON-1 approach?

Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL.
Interview by Esther Drain.
Advertisment
Professor Stephen Ansell (Mayo Clinic, USA) discusses who might benefit most from A+AVD upfront in HL.
Interview by Esther Drain.